Neuren Pharmaceuticals
Home
About Us
Company Overview
Company Values
Leadership Team
Corporate Directory
Product development
Product Development Pipeline
The science behind Neuren's products
Trofinetide (also known as NNZ-2566) in Rett Syndrome
Trofinetide (also known as NNZ-2566) in Fragile X Syndrome
NNZ-2591 in Phelan-McDermid syndrome
NNZ-2591 in Angelman syndrome
NNZ-2591 in Pitt Hopkins syndrome
Investor Information
Welcome
Share Price Information
Corporate Calendar
Shareholder Services
Corporate Governance
Analyst Coverage
Corporate Directory
News & Reports
ASX Announcements
Annual and Interim Reports
Scientific presentations
Investor presentations, audio, video
Email Alerts
Publications
Contact Us
Contact Us
Email Alerts
ASX Announcements
Annual and Interim Reports
Scientific presentations
Investor presentations, audio, video
Email Alerts
Publications
Home
>
News & Reports
>
Annual and Interim Reports
Font Smaller
Font larger
Print Page
Annual and Interim Reports
annual report
view the neuren pharmaceuticals
2019
interactive annual report
Annual and Interim Reports
26-Aug-2020
Half Yearly Report and Accounts
Half Yearly Report and Accounts
4-May-2020
2018 Interactive Annual Report
2018 Interactive Annual Report
26-Feb-2020
Appendix 4E and 2019 full year accounts
Appendix 4E and 2019 full year accounts
28-Aug-2019
Half Yearly Report and Accounts
Half Yearly Report and Accounts
27-Feb-2019
Preliminary Final Report and statutory accounts
Preliminary Final Report and statutory accounts
31-Aug-2018
Half Yearly Report and Accounts
Half Yearly Report and Accounts
8-May-2018
2017 Interactive Annual Report
2017 Interactive Annual Report
24-Aug-2017
Half Yearly Report and Accounts
Half Yearly Report and Accounts
1-May-2017
2016 Interactive Annual Report
2016 Interactive Annual Report
23-Feb-2017
Preliminary Final Report
Preliminary Final Report
Click here for archives